C-(2-Phenyl-Cyclohexyl)-Methylamine Compounds for the Treatment of Anxiety Disorders

a technology of methylamine and methylamine, which is applied in the direction of biocide, plant growth regulator, animal husbandry, etc., can solve the problems of inducing deep-seated despair in virtually anyone, monoamine reuptake inhibitors, and standard medications that often intensify or induce anxiety states

Inactive Publication Date: 2010-09-30
GRUNENTHAL GMBH
View PDF3 Cites 0 Cited by
  • Summary
  • Abstract
  • Description
  • Claims
  • Application Information

AI Technical Summary

Benefits of technology

These compounds demonstrate an early onset of action with pronounced anxiolytic, antidepressant, and analgesic effects, reducing the risk of initial therapy-induced anxiety and suicide, and are particularly beneficial for patients resistant to standard treatments, offering a potent therapeutic option for anxiety disorders, depression, and chronic pain.

Problems solved by technology

This event would induce a deep-seated despair in virtually anyone.
A great disadvantage in this context is that the monoamine reuptake inhibitors display their anxiolytic and antidepressant action only after several weeks of treatment and achieve their full activity only after approx.
At the start of treatment of patients suffering from anxiety, and also those suffering from depression, standard medications frequently intensify or induce anxiety states, unrest, increased irritability and thoughts of suicide.

Method used

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
View more

Image

Smart Image Click on the blue labels to locate them in the text.
Viewing Examples
Smart Image
  • C-(2-Phenyl-Cyclohexyl)-Methylamine Compounds for the Treatment of Anxiety Disorders
  • C-(2-Phenyl-Cyclohexyl)-Methylamine Compounds for the Treatment of Anxiety Disorders
  • C-(2-Phenyl-Cyclohexyl)-Methylamine Compounds for the Treatment of Anxiety Disorders

Examples

Experimental program
Comparison scheme
Effect test

example 1

Preparation of (1R,2R)-[2-(3-methoxyphenyl)-cyclohexylmethyl]-methylamine hydrochloride

[0057][2-(3-Methoxyphenyl)-cyclohexylmethyl]-methylamine and (1R,2R)-[2-(3-methoxyphenyl)-cyclohexylmethyl]-methylamine, in particular the hydrochloride salt thereof, are prepared as follows:

[0058]3.16 ml (25.2 mmol) phenyl chloroformate were added dropwise to a solution of 5.67 g (22.9 mmol) (1R,2R)-[2-(3-methoxyphenyl)-cyclohexylmethyl]-dimethylamine in 390 ml dry toluene at the boiling point. After the mixture had been heated under reflux for three hours, it was cooled to 20° C., and washed successively with 100 ml each of sodium hydroxide solution (2.5N), distilled water, hydrochloric acid (1N) and a saturated sodium chloride solution. It was dried over sodium sulfate and evaporated in vacuo. The residue was taken up in 192.5 ml ethylene glycol and 46 ml sodium hydroxide solution (5N) and the mixture was stirred at 110° C. for a total of 8 hours, it being topped up twice with 10 ml sodium hydr...

example 2

Preparation of (1R,2R)-3-(2-methylaminomethyl-cyclohexyl)-phenol hydrochloride

[0059]3.55 g (15.2 mmol) of the product from example 1 were stirred under reflux in 4.59 ml hydrobromic acid (47-48% HBr) for 7.5 h. After cooling, ice / water was added and the mixture was then rendered alkaline with sodium hydroxide solution (6N). It was extracted three times with 50 ml ethyl acetate each time. The extracts were washed with a saturated sodium chloride solution, dried over sodium sulfate and evaporated in vacuo. The residue (2.91 g) was dissolved in 16.4 ml 2-butanone and converted into the hydrochloride with 1.63 ml trimethylchlorosilane as described under example 1. By this procedure, 2.98 g (76.5% of theory) of the title compound were obtained as a slightly yellow-colored solid which melted at 173-175° C.

example 3

Preparation of sulfuric acid mono-(1R,2R)-[3-(2-dimethylaminomethyl-cyclohexyl)-phenyl]ester

[0060]Sulfuric acid mono-[3-(2-dimethylaminomethyl-cyclohexyl)-phenyl]ester or sulfuric acid mono-(1R,2R)-[3-(2-dimethylaminomethyl-cyclohexyl)-phenyl]ester was prepared as follows:

[0061]15.9 g (4.70 mmol) of a 2.9% strength solution of sulfuric acid in dimethylformamide were added dropwise to a solution of 1.00 g (3.92 mmol) (1R,2R)-3-(2-dimethylaminomethyl-cyclohexyl)-phenol; hydrochloride and 0.94 g (4.70 mmol) dicyclohexylcarbodiimide in 20 ml dimethylformamide at 0° C., while stirring. When the addition had ended, the mixture was stirred further for another 10 minutes and a pH of 9 was then established with dilute ammonium hydroxide solution. The precipitate formed was separated off, washed with ethyl acetate and dried in vacuo. 0.26 g (21% of theory) of the title compound was obtained in this way as a white solid.

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
Login to View More

PUM

No PUM Login to View More

Abstract

Pharmaceutical formulations of [2-(3-methoxyphenyl)-cyclohexylmethyl]-dimethylamine and the metabolites thereof for treating anxiety, anxiety attacks and disorders as well as depression. Related methods of treating anxiety and anxiety attacks or depression are also provided, including methods of administering the active compounds as adjuvants to an antidepressant.

Description

CROSS-REFERENCE TO RELATED APPLICATIONS[0001]This application is a division of co-pending application Ser. No. 11 / 440,005, filed May 25, 2006, now abandoned, which in turn was a continuation of International patent application no. PCT / EP2004 / 013439, filed Nov. 26, 2004 designating the United States of America, and published in German on Jun. 9, 2005 as WO 2005 / 051375, the entire disclosure of which is incorporated herein by reference. Priority is claimed based on Federal Republic of Germany patent application no DE 103 56 362.8, filed Nov. 28, 2003, the disclosure of which is likewise incorporated herein by reference.FIELD OF THE INVENTION[0002]The invention relates to pharmaceutical formulations of [2-(3-methoxyphenyl)-cyclohexylmethyl]-dimethylamine and the metabolites thereof for treating anxiety, anxiety attacks and disorders as well as depression. Related methods of treating anxiety and anxiety attacks or depression are also provided, including methods of administering the acti...

Claims

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
Login to View More

Application Information

Patent Timeline
no application Login to View More
Patent Type & AuthorityApplications(United States)
IPC IPC(8): A61K31/351A61K31/138A61K31/255A61P25/24A61P25/22A61K31/137A61K31/145A61K31/35
CPCA61K31/137A61K31/35A61K31/145A61P1/14A61P17/00A61P17/04A61P21/00A61P25/00A61P25/04A61P25/06A61P25/18A61P25/22A61P25/24A61P25/28A61P25/30A61P3/04
InventorBLOMS-FUNKE, PETRAENGLBERGER, WERNERHENNIES, HAGEN-HEINRICH
OwnerGRUNENTHAL GMBH